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Mini Review 
Abstract 
Soft tissue sarcomas (STS) are usually high-
ly malignant. Bone metastasis is less com-
mon in STS but it significantly affects pa-
tients` quality of life and also is indicator of 
poor prognosis. Different types of imaging 
modalities are available for diagnosis and 
follow-up of STS. Bone scintigraphy is a 
sensitive and cost effective method for 
screening bone metastases however it`s poor 
specificity must be covered by other imag-
ing methods like computed tomography. 
More sophisticated methods are available 
including whole body magnetic resonance 
imaging (MRI) and positron emission to-
mography (PET). Equipment limitations and 
high costs are the main problems with 
ofthese methods. 
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Introduction 
Soft tissue sarcomas (STS) are groupof 
heterogeneous neoplasms, accounting for 
less than 1% of all human malignancies. 
STS have tendency to spread via 
bloodstream.Half of STS patients develop 
metastatic disease1. The lungs are the most 
common sites of the metastasis 2. In a 
study conducted by Yoshikawaet al.,the 
incidence of skeletal metastasis in STS 
patients was 10%3. Additionally Skeletal 
involvement was different in subtypes of 
STS. Alveolar soft-part sarcoma, 
dedifferentiatedliposarcoma, angiosarcoma 
and rhabdomyosarcomashowed a higher 
incidenceof skeletal metastases3, 4. 
Skeletal metastasis leads to skeletal related 
events (SREs). “The term SRE is used to 
encompass common complications of bone 
metastases such as pathologic fracture 
secondary to a bone metastasis, spinal cord 
compression or the need for surgery or 
radiotherapy to bone”5. SREs can have 
significant adverse effects on patients’ 
quality of life;accordingly, clinicians must 
consider management of the SREs in STS 
patients, even if survival is limited. 
Additionally, with the recent advances, 
overall survival in STS patients has 
increased and new imaging techniques 
have improved the diagnosis of bone 
metastasis4. 
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Selecting the appropriateimaging 
modalitiesis an important issue. A 
diagnostic imaging modality must be cost-
effective and accurate for medical 
interventions. Scintigraphy, positron 
emission tomography (PET) and whole 
body MRI are the main diagnostic 
modalities. Other imaging techniques such 
asradiography, computed tomography (CT) 
andMRIcan be used to confirm the 
diagnosis and evaluate the extent of 
metastasis and its characteristics 6.  
In this brief review, we will discuss the 
available imaging modalities for diagnosis 
of skeletal metastasis in STS patients. 
Association of symptoms with bone metastases 
The most common signs of bone 
metastases are pain, fracture, spinal cord 
compression, and hypercalcemia.Bone pain 
is often the first symptom of bone 
involvement. Most patients (75%) 
diagnosed with bone metastases experience 
severe bone pain 7, 8.The pain in patients 
with bone metastases can be due to various 
causes including, tumor-induced 
osteolysis, direct infiltration of nerves, 
production of endothelins and nerve 
growth factors from local tissue, 
stimulation of ion channels and production 
of growth factors and cytokines from the 
tumor9, 10. Also, bone metastases can 
weaken bones and lead to pathological 
fractures. Subsequently, these fractures 
often cause severe pain 3, 8. Meijer et al. 
found a correlation between the location of 
bone metastasisand bone pain7  
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Spinal cord compression, which is another 
sign of bone metastases can lead to pain in 
the neck, back and lower limbs with or 
without neurological complication and 
mechanical instability 10. 
Patients may experience different 
symptoms as a result of diffuse bone 
marrow infiltration which usually happens 
in those who have received radiotherapy or 
chemotherapy. Patients whose red blood 
cells are affected, experience anemia, 
fatigue, and weakness. decreased white 
blood cell count increases the risk of 
infection. A low platelet count may lead to 
coagulation defects 8, 9. In some patients, 
swelling is reported as a symptom of bone 
metastases 3. 
Hypercalcemia is a nonspecific symptom 
and leads to constipation, nausea, and 
anorexia, however, it is a significant 
complication in the treatment of the STS 
and indicates a worse prognosis 6. 
Chow et al. studied five hundred eighteen 
cancer patients with bone metastasis and 
identified three symptoms clusters: 1) the 
most common symptoms including fatigue, 
pain, drowsiness and poor sense of well-
being, 2) depression and anxiety, which 
was more prevalent in women, and 3) the 
rare symptoms including shortness of 
breath, nausea, and anorexia 11. 
The best diagnostic modality 
Imaging techniqueshave significant roles 
in detection, follow-up, monitoring and 
planning treatment of bone metastases12. 
The most common imaging modalitiesfor 
finding bone metastasisin soft tissue 
sarcoma patients are radiography, bone 
scintigraphy, computed tomography (CT) 
scanning, radioisotope scanning’s like 
PET, and magnetic resonance imaging 
(MRI). 
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Radiography is a cheap and fast imaging 
technique. It is usually used to confirm the 
findings of other methods, however 
because of poor sensitivity it is not 
recommended as a screening method for 
bone metastases 13, 14. 
Computed tomography (CT) can evaluate 
metastases within bone marrow before 
bone destruction has occurred. This 
technique can be usedfor detecting 
metastasis in axial bones.In addition, it can 
give us information about the size and 
structure of the metastasis, which is 
important in selection of an orthopedic 
implant. CT does not have screening role 
for bone metastases because it is time-
consuming and it imposes high amount of 
radiation13, 15-18. 
Bone scintigraphy is more sensitive than 
radiography and CT for detection of 
metastases in bone marrow, but it has poor 
specificity.Because some trauma and 
degenerative diseases can increase tracer 
uptake which canmimic skeletal metastases 
19, 20. Nevertheless, it is the most cost-
effective whole body screening technique 
of bone metastases6, 21. A study conducted 
by Baraiet al. showed that routine 
scintigraphy in STS has a relatively low 
yield. This study suggests preforming 
scintigraphy only for patients with bone 
pain, however in this case asymptomatic 
patients may be missed19. 
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Positron emission tomography (PET) 
especially with 18F-fluorodeoxyglucose 
(FDG) has an important role in the 
detection of bone metastases 22. PET is 
expensive and takes longer time compared 
to other imaging modalities23, 24.  
Today, whole body magnetic resonance 
imaging (MRI) and FDG-PET may 
improve detection of bone metastasis. MRI 
is a fast and simple modality for evaluating 
the axial skeleton. In MRI, most false 
negative detections were located in small 
and flat bones such as the skull, the ribs, 
and the carpal bone13, 18, 20. 
Daldrup-Link et al. compared the 
diagnostic accuracy of whole-body 
magnetic resonance imaging (MRI), FDG-
PET and bone scintigraphy for identifying 
bone metastasis. In this study, FDG-PET 
showed the highest sensitivity (86%) 
compared to MRI (82%) and bone 
scintigraphy (71%)20. Currently, it seems 
that the best diagnostic modality of bone 
metastases in patients with soft tissue 
sarcoma is utilizing a combination of 
imaging techniques. Generally, the first 
choice of screening is bone scintigraphy 
because of its high sensitivity and cost-
effectiveness . However, bone scintigraphy 
needs to be followed by other methods for 
an accurate diagnosis. Bone scintigraphy 
and FDG-PET are useful to detect bone 
metastases in asymptomatic patients 7, 25  
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The most important limitation of accurate 
methods like FDG-PET and whole-body 
MRI is their high cost.  
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